Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Zymeworks Inc's Business Segments
Zymeworks Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Drug Supply
Total Revenue
$ 5
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Drug Supply36.3%
- Jazz Royalties24.7%
- BeOne Royalties9.5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Drug Supply | $ 2 | 36.3% |
| Jazz Royalties | $ 1 | 24.7% |
| BeOne Royalties | $ 0 | 9.5% |
Annual Results
Revenue Share by Reportable Segment - FY
- Drug Supply36.3%
- Jazz Royalties24.7%
- BeOne Royalties9.5%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Drug Supply | $ 2 | 36.3% |
| Jazz Royalties | $ 1 | 24.7% |
| BeOne Royalties | $ 0 | 9.5% |
Description of Zymeworks Inc
Zymeworks Inc is a biopharmaceutical company that primarily focuses on the development of multifunctional biotherapeutics in the areas of immuno-oncology, oncology, and autoimmune disorders. Their proprietary platforms, Azymetric and EFECT, enable the creation of highly differentiated and optimized bi-specific and multi-specific antibodies.
The Azymetric platform utilizes a unique approach that enables the engineering of antibodies to effectively target two different antigens simultaneously. This platform creates symmetrical antibodies that bind to both antigens with high affinity in a stable configuration, which provides superior disease-fighting capabilities. The Azymetric technology also allows for the creation of bi- and multi-specific antibodies with longer half-lives and reduced immunogenicity compared to traditional antibody therapies.
EFECT is a separate bi-specific antibody platform that is designed to activate the immune system by selectively targeting T-cell receptors on tumor cells. EFECT-engineered antibodies are created by fusing two monoclonal antibodies, one of which binds directly to tumor cells, and the other is designed to engage T-cells.
Zymeworks Inc has a portfolio of product candidates in various stages of development, including zanidatamab (ZYBRESTAT), a bi-specific antibody for the treatment of advanced solid tumors, and ZW25, a bi-specific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in many human cancers.
The company has partnerships and collaborations with other biopharmaceutical companies and research organizations, including Merck, Eli Lilly, Celgene, Kite Pharma, and ImmunoGen. They have also received funding from venture capitalists, investors, and government agencies.
Zymeworks Inc was founded in 2003 and is headquartered in Vancouver, British Columbia, Canada. The company has a workforce of over 400 employees, including experienced scientists, engineers, and clinicians. Zymeworks Inc aims to transform the lives of people living with serious diseases by advancing the science of biotherapeutics.
The Azymetric platform utilizes a unique approach that enables the engineering of antibodies to effectively target two different antigens simultaneously. This platform creates symmetrical antibodies that bind to both antigens with high affinity in a stable configuration, which provides superior disease-fighting capabilities. The Azymetric technology also allows for the creation of bi- and multi-specific antibodies with longer half-lives and reduced immunogenicity compared to traditional antibody therapies.
EFECT is a separate bi-specific antibody platform that is designed to activate the immune system by selectively targeting T-cell receptors on tumor cells. EFECT-engineered antibodies are created by fusing two monoclonal antibodies, one of which binds directly to tumor cells, and the other is designed to engage T-cells.
Zymeworks Inc has a portfolio of product candidates in various stages of development, including zanidatamab (ZYBRESTAT), a bi-specific antibody for the treatment of advanced solid tumors, and ZW25, a bi-specific antibody that targets two different epitopes of the HER2 protein, which is overexpressed in many human cancers.
The company has partnerships and collaborations with other biopharmaceutical companies and research organizations, including Merck, Eli Lilly, Celgene, Kite Pharma, and ImmunoGen. They have also received funding from venture capitalists, investors, and government agencies.
Zymeworks Inc was founded in 2003 and is headquartered in Vancouver, British Columbia, Canada. The company has a workforce of over 400 employees, including experienced scientists, engineers, and clinicians. Zymeworks Inc aims to transform the lives of people living with serious diseases by advancing the science of biotherapeutics.
Zymeworks Inc. is a leading biotechnology company known for its innovative approach to developing multifunctional biotherapeutics. The company is focused on creating personalized medicine solutions through sophisticated drug discovery and development techniques. Zymeworks operates through three key segments: Discovery Research, Preclinical Development, and Clinical Development, each contributing to a comprehensive pipeline of therapeutic candidates and advanced platforms.
1. Discovery Research Segment
This segment concentrates on the early stages of drug development, focusing on the identification and validation of potential drug candidates. Zymeworks employs state-of-the-art computational methods alongside extensive biological assays to discover novel therapeutic targets. The Discovery Research segment is underpinned by several proprietary protein engineering technologies that allow for the generation of high-affinity drug candidates tailored for specific therapeutic indications.
Products:
- Azymetric Platform: This bispecific antibody platform enables the design of antibodies that can bind to two different targets simultaneously, enhancing therapeutic efficacy through localized treatment of diseases. The platform has applications in various indications, allowing for greater specificity and potency.
- EFECT Platform: The Enhanced Format Enabling Comprehensive Therapies (EFECT) platform is designed for the creation of highly specific and stable monoclonal antibodies. This technology allows for the targeting of various disease states, improving the potential for successful therapeutic interventions.
- AlbuCORE Platform: This platform facilitates the development of albumin-binding domains, which improve the pharmacokinetic profile and efficacy of therapeutics by enhancing their circulation time in the bloodstream. The technology is designed for targeted drug delivery, maximizing therapeutic effects while minimizing off-target activity.
Services:
- Drug Discovery Services: Zymeworks provides comprehensive drug discovery services, which include but are not limited to assay development, target identification, lead optimization, and the thorough validation of drug candidates to ensure their therapeutic potential meets clinical requirements.
- Protein Engineering Services: The company leverages its proprietary platforms to engineer proteins with tailored properties, emphasizing optimized stability, specificity, and potency, to suit various therapeutic applications.
Preclinical Development Segment
In this segment, Zymeworks focuses on enhancing and characterizing the drug candidates sourced from Discovery Research. The objective is to conduct extensive preclinical studies to assess the safety profile, pharmacokinetics, and overall efficacy of these drug candidates in preparation for clinical trials.
Products:
- ZW25: This bispecific antibody is designed to simultaneously target two distinct epitopes on the HER2 protein, which is frequently overexpressed in various solid tumors. ZW25 has shown promising clinical efficacy in treating HER2-positive breast cancer, gastric cancer, and biliary tract cancer, positioning it as a key asset in Zymeworks pipeline.
- ZW49: This product is a bispecific antibody-drug conjugate that targets HER2-expressing tumors. By combining a bispecific antibody with a potent cytotoxic payload, ZW49 facilitates targeted delivery of the drug to malignant cells, thereby improving treatment effectiveness while minimizing harm to healthy tissues.
Services:
- Preclinical Development Services: Zymeworks offers a robust suite of preclinical development services, including in-vivo pharmacology studies to assess therapeutic effectiveness, toxicology evaluations to identify potential safety concerns, and comprehensive formulation development to ensure optimal drug delivery mechanisms.
Clinical Development Segment
The Clinical Development segment encompasses the advancement of drug candidates into human trials, focusing on evaluating their safety and efficacy. Zymeworks collaborates closely with regulatory agencies to pave the way for obtaining approval for the commercialization of its innovative therapies.
Products:
- ZW25: Currently in Phase II clinical trials, ZW25 is focused on evaluating its effectiveness in treating HER2-positive breast cancer, gastric cancer, and biliary tract cancer.
- ZW49: This drug candidate is undergoing Phase I clinical trials, assessing its safety and efficacy for patients with HER2-expressing tumors, and aims to establish its therapeutic potential.
Services:
- Clinical Development Services: Zymeworks provides comprehensive clinical development services, which include clinical trial design, management of regulatory submissions, and oversight of clinical site operations to ensure robust data collection and compliance with regulatory standards.
In summary, Zymeworks Inc. exemplifies a dynamic biotechnology company dedicated to advancing therapeutic solutions across a range of serious diseases through its innovative platforms, comprehensive drug development services, and commitment to improving patient outcomes.
1. Discovery Research Segment
This segment concentrates on the early stages of drug development, focusing on the identification and validation of potential drug candidates. Zymeworks employs state-of-the-art computational methods alongside extensive biological assays to discover novel therapeutic targets. The Discovery Research segment is underpinned by several proprietary protein engineering technologies that allow for the generation of high-affinity drug candidates tailored for specific therapeutic indications.
Products:
- Azymetric Platform: This bispecific antibody platform enables the design of antibodies that can bind to two different targets simultaneously, enhancing therapeutic efficacy through localized treatment of diseases. The platform has applications in various indications, allowing for greater specificity and potency.
- EFECT Platform: The Enhanced Format Enabling Comprehensive Therapies (EFECT) platform is designed for the creation of highly specific and stable monoclonal antibodies. This technology allows for the targeting of various disease states, improving the potential for successful therapeutic interventions.
- AlbuCORE Platform: This platform facilitates the development of albumin-binding domains, which improve the pharmacokinetic profile and efficacy of therapeutics by enhancing their circulation time in the bloodstream. The technology is designed for targeted drug delivery, maximizing therapeutic effects while minimizing off-target activity.
Services:
- Drug Discovery Services: Zymeworks provides comprehensive drug discovery services, which include but are not limited to assay development, target identification, lead optimization, and the thorough validation of drug candidates to ensure their therapeutic potential meets clinical requirements.
- Protein Engineering Services: The company leverages its proprietary platforms to engineer proteins with tailored properties, emphasizing optimized stability, specificity, and potency, to suit various therapeutic applications.
Preclinical Development Segment
In this segment, Zymeworks focuses on enhancing and characterizing the drug candidates sourced from Discovery Research. The objective is to conduct extensive preclinical studies to assess the safety profile, pharmacokinetics, and overall efficacy of these drug candidates in preparation for clinical trials.
Products:
- ZW25: This bispecific antibody is designed to simultaneously target two distinct epitopes on the HER2 protein, which is frequently overexpressed in various solid tumors. ZW25 has shown promising clinical efficacy in treating HER2-positive breast cancer, gastric cancer, and biliary tract cancer, positioning it as a key asset in Zymeworks pipeline.
- ZW49: This product is a bispecific antibody-drug conjugate that targets HER2-expressing tumors. By combining a bispecific antibody with a potent cytotoxic payload, ZW49 facilitates targeted delivery of the drug to malignant cells, thereby improving treatment effectiveness while minimizing harm to healthy tissues.
Services:
- Preclinical Development Services: Zymeworks offers a robust suite of preclinical development services, including in-vivo pharmacology studies to assess therapeutic effectiveness, toxicology evaluations to identify potential safety concerns, and comprehensive formulation development to ensure optimal drug delivery mechanisms.
Clinical Development Segment
The Clinical Development segment encompasses the advancement of drug candidates into human trials, focusing on evaluating their safety and efficacy. Zymeworks collaborates closely with regulatory agencies to pave the way for obtaining approval for the commercialization of its innovative therapies.
Products:
- ZW25: Currently in Phase II clinical trials, ZW25 is focused on evaluating its effectiveness in treating HER2-positive breast cancer, gastric cancer, and biliary tract cancer.
- ZW49: This drug candidate is undergoing Phase I clinical trials, assessing its safety and efficacy for patients with HER2-expressing tumors, and aims to establish its therapeutic potential.
Services:
- Clinical Development Services: Zymeworks provides comprehensive clinical development services, which include clinical trial design, management of regulatory submissions, and oversight of clinical site operations to ensure robust data collection and compliance with regulatory standards.
In summary, Zymeworks Inc. exemplifies a dynamic biotechnology company dedicated to advancing therapeutic solutions across a range of serious diseases through its innovative platforms, comprehensive drug development services, and commitment to improving patient outcomes.